Bausch + Lomb Announces New Scientific Data, Educational Events at Upcoming American Academy of Optometry and American Academy of Ophthalmology Annual Meetings

VAUGHAN, Ontario, Oct. 6, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced more than 20 scientific presentations at the American Academy of Optometry Annual Meeting in Boston, October 8-11, 2025, and four poster presentations at the American Academy of Ophthalmology Annual Meeting in Orlando, October 18-20, 2025. The company will also host several educational events at both meetings.

Presentations in Boston will feature phase 4 data detailing early patient-reported symptom relief following initial use of MIEBO® (perfluorohexyloctane ophthalmic solution). Additional data will showcase key products from the company’s broad eye care portfolio, including XIIDRA® (lifitegrast ophthalmic solution) 5%, Bausch + Lomb INFUSE® for Astigmatism daily disposable contact lenses, Zenlens® scleral lenses and the Arise™ Orthokeratology Lens System. In Orlando, presentations will highlight surgical data, including use of the TENEO™ Excimer Laser.

Sponsored educational events at both meetings will focus on topics related to dry eye management and feature Bausch + Lomb products including Blink® NutriTears™ nutritional supplement, MIEBO, VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024%, Blink® eye drops, LUMIFY® Preservative Free redness reliever eye drops and AREDS formula eye vitamins.

See below for the complete list of Bausch + Lomb events and scientific presentations.

American Academy of Optometry Annual Meeting

Poster Presentations

  • “Chronic Corneal Inflammation Following Chemical Ocular Injury: Development of Limbal Stem Cell Deficiency and Steel Wool Keratopathy.” Wang et al.
  • “Early Patient-Reported Satisfaction in Patients Initiated on Perfluorohexyloctane for Dry Eye Disease.” Quint et al.
  • “Early Response to Treatment with Perfluorohexyloctane Ophthalmic Solution for Dry Eye Disease.” Kannarr et al.
  • “Early Symptom Relief with Lifitegrast Ophthalmic Solution 5.0% in Patients with Dry Eye Disease: A Post Hoc Analysis of Two Randomized Clinical Trials.” Lang et al.
  • “Effects of Topical Prostaglandin Analogs on Intraocular Pressure and Ocular Growth in Defocus-Induced Guinea Pig Myopia Model.” Dhungel et al.
  • “Fit and Stability of the Arise Orthokeratology Lens with Toric Posterior Peripheral Curves in Patients with Myopia.” Harthan et al.
  • “Higher Order Aberration Correction in Scleral Lenses for Keratoconus.” Nelson et al.
  • “Making Magic with Scleral Multifocals.” Gidosh N.
  • “Multi-Country Real-World Evaluation of a Custom Scleral Lens System.” Hoffman et al.
  • “One-week Dispensing Evaluation of Revive Toric Soft Contact Lenses.” Schafer et al.
  • “Patient Characteristics and Clinical Practice Patterns in Inflammatory Dry Eye Disease: Real-World Insights.” Shen Lee et al.
  • “Patient-Reported Outcomes Following Use of a Tri-Action Lipid-Hyaluronic Acid Eye Drop in Habitual Lubricant Users with Dry Eye.” Poteet J.
  • “Perioperative Use of Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Undergoing Cataract Surgery.” Koetting et al.
  • “Pediatric Aphakia: When Recurrent Red Eye Leads to Alternate Contact Lens Considerations.” Grant et al.
  • “Practitioner Satisfaction and Experience with a Novel Daily Disposable Toric Contact Lens in a Real-World Evaluation.” Schaeffer et al.
  • “Power Profiles of Soft Simultaneous Imaging Multifocal Contact Lenses.” Montani et al.
  • “Real-World Assessment of a Preservative-Free Lubricating Eye Drop in Habitual Drops to Users with Dry Eyes.” Tsai J.
  • “Safety and Effectiveness of the Arise Orthokeratology Lens with Toric Posterior Peripheral Curves in Patients with Myopia: Open-Label Study.” Harthan et al.
  • “Short- and Long-Term Adherence and Patient Characteristics of Adopters of Perfluorohexyloctane in Dry Eye Disease.” Alexander et al.
  • “Under Pressure: Managing Mirvetuximab-Induced Keratopathy in a Patient with Primary Open-Angle Glaucoma.” Wong et al.
  • “Unmet Needs in Dry Eye: Real-World Insights from Habitual Users of OTC Lubricating Eye Drops.” Lang J.

Educational Events
Wednesday, October 8
A Family of Eyecare Products with Innovations for Every Stage of Life

  • 12:00-1:00 p.m. ET; Thomas M. Menino Convention Center, 415 Summer Street, Meeting Level 2, Room: 203
  • Speakers: Kriti Bhagat, OD; Mark Schaeffer, OD, FAAO; Selina McGee, OD, FAAO

 

Managing Patients with Both Glaucoma & Dry Eye Disease

  • 5:30-6:30 p.m. ET; Thomas M. Menino Convention Center, 415 Summer Street, Meeting Level 2, Room: 204 AB
  • Speakers: Selina R. McGee, OD, FAAO; Michael Chaglasian, OD, FAAO

Managing Patients with Both Glaucoma & Dry Eye Disease

  • Registration at 6:45 p.m. ET, program at 7:00 p.m. ET; Del Frisco’s Double Eagle Steakhouse, 250 Northern Ave, Suite 200
  • Speakers: Ben Gaddie, OD, FAAO; Nora Lee Cothran, OD, FAAO
  • Registration link

Thursday, October 9
New LUMIFY Preservative Free: Taking Redness Relief to The Next Level

  • 8:00-8:45 a.m. ET; Thomas M. Menino Convention Center, 415 Summer Street, Meeting Level 2, Room: 213
  • Speaker: Kriti Bhagat, OD

 

Fast Tracking Dry Eye Management: Integrating Science and Practice

  • 12:00-1:00 p.m. ET; Thomas M. Menino Convention Center, 415 Summer Street, Meeting Level 2, Room: 212
  • Speakers: Mile Brujic, OD, FAAO; Jessilin Quint, OD, MBA, FAAO

AREDS: A Summary of Recent Clinical Updates

  • 5:30-6:30 p.m. ET; Thomas M. Menino Convention Center, 415 Summer Street, Meeting Level 2, Room: 204 AB
  • Speaker: Jeffry Gerson, OD, FAAO

Know Your Dry Eye: Navigating the Challenges of Real-World Dry Eye Cases

  • Registration at 6:45 p.m. ET, program at 7:00 p.m. ET; Davio’s Seaport, 26 Fan Pier Boulevard
  • Speakers: Doug Devries, OD; Tracy Doll, OD, FAAO
  • Registration link

Friday, October 10
OTC Eye Drops: More Than Meets the Eye, featuring NEW Blink and LUMIFY products

  • 8:00-8:45 a.m. ET; Thomas M. Menino Convention Center, 415 Summer Street, Meeting Level 2, Room 203
  • Speaker: Cecelia Koetting, OD, FAAO, DipABO

The Puzzle of Dry Eye: Targeted Approaches to a Multifactorial Condition

  • 12:00-1:00 p.m. ET; Thomas M. Menino Convention Center, 415 Summer Street, Meeting Level 2, Room: 203
  • Speakers: Cory Lappin, OD, MS, FAAO; Cecelia Koetting, OD, FAAO, DipABO

American Academy of Ophthalmology Annual Meeting

Poster Presentations

  • “Excimer Laser Trabeculostomy (ab interno) in Glaucoma as Standalone or with Phacoemulsification: A Systematic Review & Meta-Analysis.” Toeteberg-Harms et al.
  • “Glaucoma Surgery in Uveitis: Outcomes and Factors Influencing Surgical Utilization in the American Academy of Ophthalmology IRIS® Registry.” Mosenia et al.
  • “Real-World Outcomes of a Recently Approved Excimer Laser System to Perform LASIK for Myopia and Myopic Astigmatism.” Waring IV et al.
  • “Suprachoroidal Space Changes with Suprachoroidal Injections of Triamcinolone Acetonide.” Sazhnyev et al.

Educational Events
Friday, October 17
Know Your Dry Eye: Navigating the Challenges of Real-World Dry Eye Cases

  • Registration at 7:15 p.m. ET, program at 7:30 p.m. ET; Vito's Chophouse, 8633 International Dr.
  • Speakers: Mark Milner, MD; Sheri Rowan, MD
  • Registration link

 

Saturday, October 18
Fast Tracking Dry Eye Management: Integrating Science and Practice

  • Registration at 6:45 p.m. ET, Program at 7:00 p.m. ET; Vito's Chophouse, 8633 International Dr.
  • Speakers: Marguerite McDonald, MD; Brandon Ayres, MD
  • Registration link

###

Important Safety Information for MIEBO

INDICATION
MIEBO (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

Click here for full Prescribing Information for MIEBO.

Important Safety Information for XIIDRA

Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for full Prescribing Information for Xiidra.

Important Safety Information for Arise™ Orthokeratology Lens System

INDICATIONS FOR USE
Boston Orthokeratology (oprifocon A) shaping lenses for overnight wear are indicated for use in the reduction of myopic refractive error in non-diseased eyes. The lenses are indicated for overnight wear as part of the Bausch + Lomb Vision Shaping Treatment VST® process for the temporary reduction of myopia up to 5.00 diopters with eyes having astigmatism up to 1.50 diopters. The lenses may only be disinfected using a chemical disinfection system.

SAFETY INFORMATION

CONTRAINDICATIONS
DO NOT USE the Boston Orthokeratology (oprifocon A) shaping lenses when any of the following conditions exist:

  • Acute and sub-acute inflammations or infection of the anterior chamber of the eye
  • Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids
  • Severe insufficiency of tears (dry eyes)
  • Corneal hypoesthesia (reduced corneal sensitivity)
  • Any systemic disease which may affect the eye or be exacerbated by wearing contact lenses
  • Allergic reactions of ocular surfaces or adnexa which may be induced or exaggerated by wearing contact lenses or use of contact lens solutions
  • Allergy to any ingredient, such as mercury or thimerosal, in a solution which is to be used to care for your Boston Orthokeratology (oprifocon A) shaping lenses
  • Any active corneal infection (bacterial, fungal, or viral)
  • If eyes become red or irritated

WARNINGS
The risk of ulcerative keratitis has been shown to be greater among wearers of extended wear lenses than among wearers of daily wear lenses. The risk among extended wear use users increases the number of consecutive days that lenses are worn between removals, beginning with the first overnight use. Smoking increases the risk of ulcerative keratitis for contact lens wearers. Wearing the lenses continuously (extended wear) presents increased risk, which increases with the number of consecutive days the lenses are worn between removals. Although the safety risks of overnight wear with removal upon wakening may not be as great as with extended wear, there is still increased risk beginning with the first overnight period.

PRECAUTIONS
When selecting an appropriate lens design and parameters, the eye care practitioner should consider all factors that affect lens performance and the patient’s ocular health; including oxygen permeability, wettability, central and peripheral thickness, and optic zone diameter.

ADVERSE EVENTS
A total of 378 eyes (191 patients) were enrolled in a clinical study. There were twelve significant lens-related adverse events reported in ten subjects. All eyes that showed acuity reductions were documented as returning to normal vision, except two eyes of one subject with severe corneal staining that showed ≥2 lines loss of BSCVA. The return to pre-treatment VA was not recorded for this subject, although the subject returned to soft contact lens wear and verbally reported that vision was normal. All adverse events resolved without further complications. A separate clinical study evaluated the effect of non-spherical (toric) peripheral curves on 45 astigmatic patients who were orthokeratology lens-naïve. Among the dispensed subjects, no significant adverse events were reported.

ATTENTION: Refer to the package insert for a complete listing of indications, warnings and precautions, clinical trial information, etc.

CAUTION: Federal (USA) law restricts this device to the sale by, or on the order of a licensed practitioner.

Important Safety Information for VYZULTA

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued.
  • Gradual changes to eyelashes may occur, including increased length, thickness, color, number of eyelashes and/or direction of eyelash growth. These changes may result in a difference in appearance of each eye. These changes are usually reversible after VYZULTA treatment is discontinued.
  • Avoid touching the tip of the container to the eye or any other surface, including a finger, in order to avoid contamination of the solution by bacteria. Serious damage to the eye and possible loss of vision may result from using contaminated solutions.
  • Tell your doctor immediately about any change in your eye, any eye condition that develops, any sudden change in your vision, any eye side effects, or if you have eye surgery.
  • Remove contact lenses before putting VYZULTA in your eyes. Lenses may be reinserted 15 minutes later.
  • If you are using other eye drops in addition to VYZULTA, wait 5 minutes between using each type of eye drop.
  • The most common side effects seen in studies were eye redness, eye irritation, eye pain, and pain after putting the drops in your eye.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here to see full Prescribing Information.

Important Safety Information for Technolas Teneo 317 Model 2 System

Indications for Use. The Technolas Teneo 317 Model 2 is indicated for laser-assisted in situ keratomileusis (LASIK) in: (1) Patients for the reduction or elimination of myopic astigmatism up to -10.00 D MRSE, with sphere between -1.00 D to -10.00 D and cylinder between 0.00 and -3.00 D; (2) Patients who are 22 years of age or older; (3) Patients must have a stable refraction in the last 12 months, as documented by previous clinical recordings, i.e., the spherical and cylindrical portions of the manifest distance refraction have not progressed at a rate of more than 0.50 D per year prior to the baseline examination in the eye(s) to be treated.

WARNING. Danger of injury due to failure to observe the patient selection criteria! Failure to observe the contraindications and potential adverse effects may result in serious permanent patient injury. The usage of the laser system is limited to a specific field of applications. Observe the contraindications and potential adverse effects listed in the User Manual before selecting a patient and starting any treatment.

Contraindications. Contraindications of the Technolas Teneo 317 Model 2 include patients: (1) with any type of active connective tissue disease or autoimmune disease; (2) with signs of keratoconus, abnormal corneal topography, and degenerations of the structure of the cornea (including but not limited to pellucid marginal degeneration); (3) with significant dry eyes (severe Dry Eye Syndrome). If patients have severely dry eyes, LASIK may increase the dryness. This may or may not go away. Severe eye dryness may delay healing of the flap or interfere with the surface of the eye after surgery. It may result in poor vision after LASIK; (4) for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in less than 250µ of residual corneal thickness from corneal endothelium; (5) with uncontrolled diabetes; (6) with uncontrolled glaucoma; (7) with active eye infections or active inflammation: (8) with recent herpes eye infection or problems resulting from past infections; (9) with known sensitivity to medications used for standard LASIK surgery.

Potential Risks and Side Effects: (1) Miscreated flap; (2) Subconjunctival hemorrhage or bleeding; (3) Wrinkles in flap that may require a flap lift; (4) Corneal erosion/abrasion, epithelia defect; (5) Elevated IOP; (6) Debris or foreign body under flap; (7) Epithelial ingrowth under flap; (8) Debilitating visual symptoms, especially at night; (9) Decreased or fluctuating visual acuity; (10) Decreased ability to see in low-light conditions; (11) Light sensitivity; (12) Dry Eye syndrome; (13) Inadequate treatment result; (14) Regression; (15) Corneal damage; (16) Posterior vitreous detachment or retinal detachment, floaters or vascular accidents; (17) Foreign body sensation or pain (initial postoperative days); also, potentially including chronic eye pain that is resistant to therapy referred to as neuropathic pain; (18) Infection/inflammation; (19) CTK (Central Toxic Keratopathy); (20) Medication intolerance; (21) Ptosis; (22) Cataract; (23) Ocular penetration; (24) Potential risk of psychological harm.

This is not all you need to know. Please see the User Manual for a complete list of safety information, including a full list of contraindications, warnings, precautions and risks.

Caution: Federal (U.S.) law restricts this device to sale, by or on the order of a physician.

For more information visit https://www.bauschsurgical.com/refractive/teneo/.

About Bausch + Lomb

Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

Media Contacts:
Kristy Marks
[email protected]
(908) 927-0683

Caryn Marshall
[email protected]
(908) 493-1381

© 2025 Bausch + Lomb.
MTB.0659.USA.25

Back to Press Releases